Intracellular Th Stock Analysis
ITCI Stock | USD 88.22 0.27 0.31% |
Intracellular Th is overvalued with Real Value of 72.1 and Target Price of 77.83. The main objective of Intracellular stock analysis is to determine its intrinsic value, which is an estimate of what Intracellular Th is worth, separate from its market price. There are two main types of Intracellular's stock analysis: fundamental analysis and technical analysis.
The Intracellular stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Intracellular's ongoing operational relationships across important fundamental and technical indicators.
Intracellular |
Intracellular Stock Analysis Notes
About 99.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.87. Intracellular Th had not issued any dividends in recent years. Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people. To learn more about Intracellular Th call Sharon Mates at 646 440 9333 or check out https://www.intracellulartherapies.com.Intracellular Th Investment Alerts
The company reported the previous year's revenue of 462.18 M. Net Loss for the year was (139.67 M) with profit before overhead, payroll, taxes, and interest of 95.16 M. | |
Intracellular Th currently holds about 628.74 M in cash with (124.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.64. | |
Over 99.0% of the company shares are owned by institutional investors | |
Latest headline from globenewswire.com: Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress |
Intracellular Th Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Intracellular previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
6th of March 2024 Upcoming Quarterly Report | View | |
2nd of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
6th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Intracellular Largest EPS Surprises
Earnings surprises can significantly impact Intracellular's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-08-07 | 2024-06-30 | -0.19 | -0.16 | 0.03 | 15 | ||
2024-10-30 | 2024-09-30 | -0.2 | -0.25 | -0.05 | 25 | ||
2014-11-03 | 2014-09-30 | -0.28 | -0.22 | 0.06 | 21 |
Intracellular Environmental, Social, and Governance (ESG) Scores
Intracellular's ESG score is a quantitative measure that evaluates Intracellular's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Intracellular's operations that may have significant financial implications and affect Intracellular's stock price as well as guide investors towards more socially responsible investments.
Intracellular Stock Institutional Investors
Shares | Clearbridge Advisors, Llc | 2024-06-30 | 1.7 M | Perceptive Advisors Llc | 2024-06-30 | 1.7 M | Geode Capital Management, Llc | 2024-06-30 | 1.7 M | Franklin Resources Inc | 2024-06-30 | 1.6 M | Suvretta Capital Management, Llc | 2024-06-30 | 1.6 M | Deep Track Capital, Lp | 2024-06-30 | 1.5 M | Holocene Advisors, Lp | 2024-06-30 | 1.5 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 1.4 M | Alyeska Investment Group, L.p. | 2024-06-30 | 1.4 M | Fmr Inc | 2024-06-30 | 11.2 M | Vanguard Group Inc | 2024-06-30 | 9.6 M |
Intracellular Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 9.38 B.Intracellular Profitablity
The company has Profit Margin (PM) of (0.14) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.22) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.22.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.19) | (0.20) | |
Return On Capital Employed | (0.26) | (0.28) | |
Return On Assets | (0.19) | (0.20) | |
Return On Equity | (0.24) | (0.25) |
Management Efficiency
Intracellular Th has return on total asset (ROA) of (0.0745) % which means that it has lost $0.0745 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.099) %, meaning that it created substantial loss on money invested by shareholders. Intracellular's management efficiency ratios could be used to measure how well Intracellular manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.2. The current Return On Capital Employed is estimated to decrease to -0.28. As of now, Intracellular's Non Currrent Assets Other are increasing as compared to previous years. The Intracellular's current Deferred Long Term Asset Charges is estimated to increase to about 635.1 K, while Total Assets are projected to decrease to under 410.9 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 6.17 | 5.03 | |
Tangible Book Value Per Share | 6.17 | 5.03 | |
Enterprise Value Over EBITDA | (42.41) | (40.29) | |
Price Book Value Ratio | 11.61 | 7.67 | |
Enterprise Value Multiple | (42.41) | (40.29) | |
Price Fair Value | 11.61 | 7.67 | |
Enterprise Value | 6.7 B | 7.1 B |
Intracellular showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Operating Margin (0.22) | Profit Margin (0.14) | Beta 0.973 | Return On Assets (0.07) | Return On Equity (0.1) |
Technical Drivers
As of the 13th of November 2024, Intracellular retains the Market Risk Adjusted Performance of 0.4019, downside deviation of 1.39, and Risk Adjusted Performance of 0.1112. Intracellular technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Intracellular Th Price Movement Analysis
The output start index for this execution was eleven with a total number of output elements of fifty. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Intracellular middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Intracellular Th. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Intracellular Th Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intracellular insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intracellular's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Intracellular insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Intracellular Outstanding Bonds
Intracellular issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Intracellular Th uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Intracellular bonds can be classified according to their maturity, which is the date when Intracellular Th has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boeing Co 2196 Corp BondUS097023DG73 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
Intesa Sanpaolo 571 Corp BondUS46115HAW79 | View | |
ISPIM 77 Corp BondUS46115HAU14 | View | |
ISPIM 3875 12 JAN 28 Corp BondUS46115HBD89 | View | |
ISPIM 4375 12 JAN 48 Corp BondUS46115HBE62 | View | |
ISPIM 3875 14 JUL 27 Corp BondUS46115HBB24 | View | |
US46115HBQ92 Corp BondUS46115HBQ92 | View |
Intracellular Predictive Daily Indicators
Intracellular intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Intracellular stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 23013.96 | |||
Daily Balance Of Power | (0.13) | |||
Rate Of Daily Change | 1.0 | |||
Day Median Price | 88.57 | |||
Day Typical Price | 88.45 | |||
Price Action Indicator | (0.48) | |||
Period Momentum Indicator | (0.27) | |||
Relative Strength Index | 56.32 |
Intracellular Corporate Filings
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 5th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 30th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 24th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 15th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 10th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 2nd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Intracellular Forecast Models
Intracellular's time-series forecasting models are one of many Intracellular's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Intracellular's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Intracellular Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Intracellular prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Intracellular shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Intracellular. By using and applying Intracellular Stock analysis, traders can create a robust methodology for identifying Intracellular entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (0.30) | (0.32) | |
Operating Profit Margin | (0.34) | (0.36) | |
Net Loss | (0.30) | (0.32) | |
Gross Profit Margin | 0.93 | 0.97 |
Current Intracellular Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Intracellular analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Intracellular analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
77.83 | Strong Buy | 16 | Odds |
Most Intracellular analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Intracellular stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Intracellular Th, talking to its executives and customers, or listening to Intracellular conference calls.
Intracellular Stock Analysis Indicators
Intracellular Th stock analysis indicators help investors evaluate how Intracellular stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Intracellular shares will generate the highest return on investment. By understating and applying Intracellular stock analysis, traders can identify Intracellular position entry and exit signals to maximize returns.
Begin Period Cash Flow | 150.4 M | |
Common Stock Shares Outstanding | 95.9 M | |
Total Stockholder Equity | 591.4 M | |
Tax Provision | 636 K | |
Property Plant And Equipment Net | 14.6 M | |
Cash And Short Term Investments | 497.9 M | |
Cash | 147.8 M | |
Accounts Payable | 11.5 M | |
Net Debt | -130.8 M | |
50 Day M A | 77.1444 | |
Total Current Liabilities | 123.5 M | |
Other Operating Expenses | 621.6 M | |
Non Current Assets Total | 60.5 M | |
Forward Price Earnings | 138.8889 | |
Non Currrent Assets Other | 45.9 M | |
Stock Based Compensation | 52.8 M |
Complementary Tools for Intracellular Stock analysis
When running Intracellular's price analysis, check to measure Intracellular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intracellular is operating at the current time. Most of Intracellular's value examination focuses on studying past and present price action to predict the probability of Intracellular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intracellular's price. Additionally, you may evaluate how the addition of Intracellular to your portfolios can decrease your overall portfolio volatility.
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |